News
AMPH
43.91
+0.90%
0.39
Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?
NASDAQ · 1d ago
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has US$589.4m of debt on its balance sheet. The company uses debt to fund growth, but is this a concern for shareholders? Amphastar pharmaceuticals has a strong balance sheet and is in a good position to pay off its debt. The firm grew its EBIT by 86% over the last year and has a healthy free cash flow. Amphastr Pharmaceuticals's debt is less than 1.4 times its earnings, which is considered to be conservative.
Simply Wall St · 1d ago
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
NASDAQ · 2d ago
Weekly Report: what happened at AMPH last week (0318-0322)?
Weekly Report · 3d ago
New Strong Sell Stocks for March 18th
NASDAQ · 03/18 13:15
Weekly Report: what happened at AMPH last week (0311-0315)?
Weekly Report · 03/18 09:09
Brokers Suggest Investing in Amphastar (AMPH): Read This Before Placing a Bet
NASDAQ · 03/11 13:30
Weekly Report: what happened at AMPH last week (0304-0308)?
Weekly Report · 03/11 09:09
Have Insiders Sold Amphastar Pharmaceuticals Shares Recently?
Amphastar Pharmaceuticals, Inc. Insider Michael Zasloff sold US$590k worth of stock at a price of US$47.18 per share. In the last year Amphastar pharmaceuticals insiders haven't bought any stock. The company boasts a high insider ownership of 7.1% of the company. Amphastr Pharmaceuticals has sold stock recently, but not in the last 12 months. But the company does not have the highest share price for the same period of time.
Simply Wall St · 03/09 12:30
Teva upgraded at J.P. Morgan on upcoming catalysts
J.P. Morgan reviewed its specialty pharma coverage and upgraded generic drugmaker Teva to Neutral from Underweight. Analyst cited a favorable catalyst set up in the months ahead for the company. Teva Pharmaceutical stock traded higher on Friday after the upgrade. J.p. Morgan on upcoming catalysts for Teva.
Seeking Alpha · 03/08 15:21
Amphastar a new overweight at J.P. Morgan on diverse asset portfolio
Healthcare Amphastar a new overweight at J.P. Morgan on diverse asset portfolio. The firm has a $40 price target for the company. The company's acquisition of Baqsimi from Eli Lilly is expected to boost sales in 2028. J.p. Morgan has initiated Amphastr with an overweight rating.
Seeking Alpha · 03/05 19:42
Amphastar Pharmaceuticals Initiated at Overweight by JP Morgan
Dow Jones · 03/05 11:31
Amphastar Pharmaceuticals Price Target Announced at $60.00/Share by JP Morgan
Dow Jones · 03/05 11:31
JP Morgan Initiates Coverage On Amphastar Pharma with Overweight Rating, Announces Price Target of $60
Benzinga · 03/05 11:21
U.S. RESEARCH ROUNDUP-Bark, Fleetcor Technologies, Tesla
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Bark, Fleetcor Technologies and Tesla are among the companies. The analysts raised their ratings on Bark and raised their targets for Fleetcor and Tesla. The companies are all listed on the New York Stock Exchange.
Reuters · 03/05 06:57
Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Seeking Alpha · 03/04 18:37
Weekly Report: what happened at AMPH last week (0226-0301)?
Weekly Report · 03/04 09:09
Amphastar Pharmaceuticals Becomes Oversold (AMPH)
NASDAQ · 03/01 17:23
Amphastar Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Amphastar Pharmaceuticals Inc reports quarterly adjusted earnings of 88 cents per share for the quarter ended in December. Revenue rose 31.9% to $178.11 million from the same quarter last year. The company reported quarterly income of $36.17 million.
Reuters · 03/01 05:19
Amphastar Pharmaceuticals (AMPH) Shares Cross Below 200 DMA
NASDAQ · 02/29 16:56
More
Webull provides a variety of real-time AMPH stock news. You can receive the latest news about Amphastar Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AMPH
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. It operates through two segments: finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Its portfolio also includes BAQSIMI (BAK-see-mee), which is used to treat very low blood sugar in people with diabetes ages 4 years and above.